Sativex® approved in Denmark for MS spasticity
Posted: Tue Jun 07, 2011 10:38 pm
Almirall, S.A. and GW Pharmaceuticals plc announced that the health authorities in Denmark have granted regulatory approval for Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray as an add-on therapy for the treatment of moderate to severe spasticity due to MS in patients who have not responded adequately to other anti-spasticity medication.
Regulatory approval for Sativex® has been granted after the recent change in the local laws. Sativex® is a first in class endocannabinoid system modulator for the treatment of spasticity in MS, currently available in the UK and Spain.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814